Victrex plc (OTCMKTS:VTXPF - Get Free Report) shares fell 7.1% on Tuesday . The company traded as low as $10.74 and last traded at $10.74. 605 shares changed hands during trading, an increase of 51% from the average session volume of 401 shares. The stock had previously closed at $11.57.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on VTXPF. Morgan Stanley began coverage on shares of Victrex in a report on Tuesday, February 4th. They set an "overweight" rating for the company. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Victrex in a report on Wednesday, April 16th.
View Our Latest Analysis on VTXPF
Victrex Price Performance
The company has a debt-to-equity ratio of 0.09, a current ratio of 4.39 and a quick ratio of 1.88. The firm's fifty day moving average price is $11.73 and its 200 day moving average price is $11.74.
Victrex Company Profile
(
Get Free Report)
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.
See Also
Before you consider Victrex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list.
While Victrex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
